MIRXES Pte Ltd of Singapore at MEDICA 2017 in Düsseldorf -- MEDICA Trade Fair
Manufacturers Service OEM

MIRXES Pte Ltd

2 Tukang Innovation Grove, #08-01 JTC MedTech Hub, 618305 Singapore
Singapore

Telephone +65 67797340
Fax +65 68162930
bus.dev@mirxes.com

This company is co-exhibitor of
Singapore Manufacturing Federation

Hall map

MEDICA 2017 hall map (Hall 3): stand G74

Fairground map

MEDICA 2017 fairground map: Hall 3

Our range of products

Product categories

  • 03  Diagnostics
  • 03.01  Clinical chemistry
  • 03.01.07  Gene tests / molecular biological diagnostic

Gene tests / molecular biological diagnostic

Our products

Product category: Gene tests / molecular biological diagnostic

Cancer Blood Test

MiRNA is Uniquely Suited for Personalized Medicine
 
Personalized medicine is gaining momentum and changing the landscape of healthcare globally. MiRNA is a novel class of genetic material discovered only at the dawn of the 21st century but has continuously made headlines in biomedical research worldwide. Distinct from DNA mutations, miRNA expression level changes during disease state and offers valuable information in detecting disease onset and monitoring disease progression and recurrence. Unlike other genetic materials, miRNA is exceptional stable and accessible in biofluids, making it an ideal candidate biomarker for non-invasive blood based test. MiRNA research has been growing exponentially worldwide with Frost and Sullivan bullishly projected that “advance in microRNA is predicting future in vitro diagnostic market”.

More Less

About us

Company details

Harnessing the power of miRNA to transform cancer management
MiRXES is a privately held life science research tool provider and miRNA diagnostic test developer headquartered in Singapore. MiRXES was founded by Professor Too Heng-Phon and three like-minded partners in 2014 with the vision of creating accurate, affordable and actionable molecular diagnostic tests to improve cancer management.

Our mission is to
Advance miRNA technologies to empower translational R & D
Identify novel miRNA disease biomarkers in biofluids and tissues
Develop non-invasive cancer screening and diagnostic tests
 
Forging close ties with key partners
MiRXES is a spin-off from the Bioprocessing Technology Institute of the Agency of Science Technology And Research (A*STAR) and is supported by Exploit Technologies and the National University of Singapore. MiRXES collaborates extensively with academic, clinical and industrial partners locally and globally in advancing the science and business of miRNA. MiRXES is a key partner to Singapore’s National Diagnostic Initiative.

More Less